Background The immune suppression mechanisms in pancreatic ductal adenocarcinoma (PDAC) remain unknown, but preclinical ...

KRAS基因突变在胰腺导管腺癌（PDAC）中的高频出现，使其成为研究人员梦寐以求的靶点。然而，这一领域长期以来被视为“不可成药”（undruggable）的难题。随着新技术和新思路的涌现，靶向KRAS的治疗正逐渐成为攻克PDAC的重要突破口。

Read on to learn about new genomic biomarkers that could improve prognosis and treatment strategies for pancreatic ductal ...

A new mouse study by researchers at the University of California (UC), San Diego, School of Medicine reveals that an enzyme ...

AMT-676 is under clinical development by Multitude therapeutics and currently in Phase I for Pancreatic Ductal Carcinoma.

Pancreatic cancer kills 50,000 people each year, according to the National Cancer Institute, and there are few effective ...

Pancreatic ductal adenocarcinoma remains a challenge to treat due to its complex biology and resistance mechanisms.

Actuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European Medicines Agency (EMA) for ...

Researchers at UC San Diego have discovered that the enzyme MICAL2 accelerates tumor growth in pancreatic cancer by ...

An enzyme called MICAL2 promotes tumor growth and metastasis in the most common form of pancreatic cancer, according to a new study.

Researchers assessed the association of KRAS mutations in metastatic PDAC with the clinical outcomes and responses to first-line chemotherapy regimens.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...